SCHEMBL2095035

SCHEMBL2095035

FC(F)(F)Oc1ccc(CNCc2cs[c]n2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN8A Q9UQD0 1/20 0.41
KCNN3 Q9UGI6 1/20 0.38
EPHX2 P34913 2/20 0.37
NR1H4 Q96RI1 1/20 0.37
KDM1A O60341 1/20 0.37
AVPR1B P47901 1/20 0.36
ALDH1A1 P00352 1/20 0.36
RAB9A P51151 1/20 0.36
TSHR P16473 1/20 0.36
VNN1 O95497 2/20 0.36
PPARA Q07869 2/20 0.35
PPARD Q03181 1/20 0.35
LMNA P02545 1/20 0.35
PLA2G1B P04054 1/20 0.35
MAPT P10636 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
ATG4B Q9Y4P1 1/20 0.35
PPARG P37231 1/20 0.35
HTR2C P28335 3/20 0.34
BCHE P06276 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2096405 0.83 RORC (0.38) SCN8AEPHX2ALDH1A1PPARAPPARD
SCHEMBL2096979 0.82 MAPT (0.47) EPHX2RAB9ALMNAPLA2G1BMAPT
SCHEMBL2094286 0.82 CHRM2 (0.46) ALDH1A1RAB9ASMN1; SMN2
SCHEMBL2096136 0.80 LMNA (0.51) ALDH1A1LMNAPLA2G1BATG4B
SCHEMBL2096333 0.80 KCNN3 (0.44) KCNN3EPHX2NR1H4KDM1ATSHR
SCHEMBL8348550 0.79 SCN8A (0.55) SCN8AEPHX2NR1H4KDM1AALDH1A1
SCHEMBL2090581 0.77 SLC6A4 (0.42) ALDH1A1TSHRLMNAACHE
Hydrochloric Acid SCHEMBL6122751 0.77 SCN8A (0.54) SCN8AEPHX2NR1H4KDM1AALDH1A1
SCHEMBL2091265 0.77 SMN1; SMN2 (0.42) ALDH1A1SMN1; SMN2
SCHEMBL2093728 0.77 LMNA (0.44) LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 SCN8A 3854/4885KCNN3 3834/4885EPHX2 3472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.